As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...

"This research provides crucial insights into how the immune system functions in sickle cell disease," said Dr. Karina Yazdanbakhsh, Vice President and Director of Research at New York Blood Center ...

Functional subpopulations of β-cells emerge to control pulsative insulin secretion in the pancreatic islets of mice through calcium oscillations.

Overhead, competing rings of satellites are readying cell towers in space that will eliminate dead zones down here. Since its 2021 initial offering, AST SpaceMobile has lured investors with its aim of ...

MaxCyte ( NASDAQ: MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...

The price trend for BRIACELL THERAP (BCTX) has been bearish lately and the stock has lost 28.2% over the past week. However, ...

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues. See why I ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

In this manuscript the authors established a novel three-dimensional culture system for stratified epithelia that allows epithelial cells to undergo epithelial-to-mesenchymal transition (EMT) and ...